CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 102 enrolled
Drug / intervention
Letermovir Pill +1 moredrug
Likely dose
Letermovir Pill 480 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04017962
NCT04017962Phase 2Completed
CompareCT.gov

An Open-label, Single-arm Study of Letermovir (LTV) for Prevention of Recurrent CMV Infection in High-risk Hematopoietic Cell Transplant (HCT) Recipients

Memorial Sloan Kettering Cancer Center·interventional·Posted Jul 12, 2019·Updated Aug 11, 2025

In Brief

A Phase 2 clinical trial evaluating Letermovir Pill and blood draw for CMV and 2 related conditions. Completed, enrolled 102 participants across 2 sites.

Detailed Summary

The purpose of this study is to determine of letermovir (LTC) is effective at preventing Cytomegalovirus (CMV) infection from returning in people who have already had CMV infection after a bone marrow transplant.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCMV, CMV Infection, Hematopoietic Cell Transplant
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedJul 12, 2019
Enrollment StartJul 19, 2019
Primary CompletionAug 7, 2024
Study CompletionJul 29, 2025
TodayJul 2, 2026
Enrollment to primary: 5.0 yearsPosted 7.0 years ago

Interventions

Letermovir Pilldrug

Patients enrolled on the study will receive oral LTV 480 mg daily (240 mg daily for patients receiving cyclosporine A). The maximum duration of LTV administration will be 14 weeks. Patients receiving oral medication will be administered a pill diary for drug compliance purposes. This will be administered and reconciled in clinic.

blood drawother

Collection of blood samples for CMV-CMI analysis via CMV immunity T cell panel assay on day 100. Patients with negative CMI on day 100 undergo collection of blood samples for retesting on day 180.